Dentsply Sirona completed the evaluation of strategic alternatives for Wellspect Healthcare business.
The decision to retain Wellspect as a subsidiary within the portfolio was made after considering various potential opportunities, including a sale of the business.
Retaining Wellspect is expected to deliver greater financial and strategic benefits to Dentsply Sirona stockholders.
Decision Outcome
Retaining Wellspect as a subsidiary was chosen to create more value for Dentsply Sirona stockholders compared to other alternatives.
Business Overview
Wellspect Healthcare is a category leader in the global continence care market with a strong product pipeline and significant market potential.
Financial Performance
Wellspect has demonstrated organic sales growth in recent years, including mid-single digit growth in 2024.
- The decision to retain Wellspect indicates Dentsply Sirona's commitment to improving patient outcomes and driving long-term value for stakeholders.
- Wellspect's position in the continence care market and its product portfolio make it a valuable asset within Dentsply Sirona's portfolio.
The retention of Wellspect as a subsidiary aligns with Dentsply Sirona's strategy to deliver durable, profitable growth and enhance the customer experience.